- Home
- MFA vs PCRX Comparison
MFA vs PCRX Comparison
Compare MFA & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFA
- PCRX
- Stock Information
- Founded
- MFA 1997
- PCRX 2006
- Country
- MFA United States
- PCRX United States
- Employees
- MFA N/A
- PCRX N/A
- Industry
- MFA Real Estate Investment Trusts
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- MFA Real Estate
- PCRX Health Care
- Exchange
- MFA Nasdaq
- PCRX Nasdaq
- Market Cap
- MFA 1.0B
- PCRX 1.2B
- IPO Year
- MFA N/A
- PCRX 2011
- Fundamental
- Price
- MFA $9.73
- PCRX $26.65
- Analyst Decision
- MFA Buy
- PCRX Buy
- Analyst Count
- MFA 8
- PCRX 6
- Target Price
- MFA $11.50
- PCRX $30.00
- AVG Volume (30 Days)
- MFA 1.1M
- PCRX 617.5K
- Earning Date
- MFA 11-05-2025
- PCRX 11-05-2025
- Dividend Yield
- MFA 14.79%
- PCRX N/A
- EPS Growth
- MFA 41.64
- PCRX N/A
- EPS
- MFA 0.88
- PCRX N/A
- Revenue
- MFA $284,489,000.00
- PCRX $705,848,000.00
- Revenue This Year
- MFA N/A
- PCRX $7.36
- Revenue Next Year
- MFA $16.86
- PCRX $10.07
- P/E Ratio
- MFA $11.06
- PCRX N/A
- Revenue Growth
- MFA 9.37
- PCRX 2.25
- 52 Week Low
- MFA $7.85
- PCRX $13.42
- 52 Week High
- MFA $13.45
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- MFA 41.50
- PCRX 57.10
- Support Level
- MFA $10.15
- PCRX $26.22
- Resistance Level
- MFA $10.57
- PCRX $27.50
- Average True Range (ATR)
- MFA 0.19
- PCRX 0.93
- MACD
- MFA -0.07
- PCRX -0.14
- Stochastic Oscillator
- MFA 6.67
- PCRX 50.75
About MFA MFA Financial Inc.
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.